Meeder Asset Management Inc. increased its position in Natera, Inc. (NASDAQ:NTRA – Free Report) by 25.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,565 shares of the medical research company’s stock after purchasing an additional 6,155 shares during the period. Meeder Asset Management Inc.’s holdings in Natera were worth $12,633,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Natera during the second quarter worth $2,962,770,000. K.J. Harrison & Partners Inc acquired a new stake in Natera in the second quarter valued at $5,117,000. Abbot Financial Management Inc. acquired a new stake in Natera in the second quarter valued at $1,537,000. Eagle Health Investments LP acquired a new stake in Natera in the second quarter valued at $4,302,000. Finally, BlueCrest Capital Management Ltd bought a new position in shares of Natera in the 2nd quarter valued at about $11,695,000. Institutional investors own 99.90% of the company’s stock.
Insider Activity at Natera
In other Natera news, insider Solomon Moshkevich sold 3,419 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $409.77, for a total value of $1,401,003.63. Following the transaction, the insider directly owned 101,323 shares of the company’s stock, valued at $41,519,125.71. This represents a 3.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 302 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $400.01, for a total transaction of $120,803.02. Following the completion of the transaction, the insider directly owned 195,276 shares in the company, valued at approximately $78,112,352.76. This represents a 0.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 47,056 shares of company stock worth $17,760,989. 5.05% of the stock is owned by corporate insiders.
Natera Price Performance
Shares of Natera stock opened at $289.50 on Thursday. The business has a fifty day simple moving average of $377.35 and a two-hundred day simple moving average of $272.44. Natera, Inc. has a 1 year low of $181.00 and a 1 year high of $437.41. The company has a market capitalization of $41.98 billion, a price-to-earnings ratio of -253.95 and a beta of 1.55.
Natera (NASDAQ:NTRA – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical research company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.14). The company had revenue of $793.98 million during the quarter, compared to analyst estimates of $707.54 million. Natera had a negative net margin of 5.66% and a negative return on equity of 8.61%. Natera’s revenue for the quarter was up 34.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.64) earnings per share. As a group, equities analysts anticipate that Natera, Inc. will post -1.25 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on NTRA shares. UBS Group boosted their price objective on shares of Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Royal Bank Of Canada raised their target price on shares of Natera from $350.00 to $460.00 and gave the company an “outperform” rating in a research note on Friday, September 25th. Roth Capital started coverage on shares of Natera in a research note on Thursday, October 22nd. They issued a “buy” rating and a $475.00 target price for the company. Stephens lifted their price target on Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Finally, Robert W. Baird lowered their price target on Natera from $458.00 to $403.00 and set an “outperform” rating on the stock in a research report on Monday, November 9th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $394.31.
View Our Latest Stock Analysis on Natera
About Natera
Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.
Recommended Stories
- Five stocks we like better than Natera
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
